CVE-2026-8599
MEDIUM SEVERITYCVSS Score & Metrics
Base Score
6.4 / 10
Vector String
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
Vulnerability Description
The MailerPress – Email Marketing, Newsletter, Email Automation & WooCommerce Emails plugin for WordPress is vulnerable to Stored Cross-Site Scripting via Campaign HTML Content Field in all versions up to, and including, 2.0.4 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with author-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page. The public-facing campaign preview endpoint (/mp-email/{id}-slug/) is not affected by this vulnerability, as it applies a Content-Security-Policy header blocking all inline scripts; exploitation is limited to the admin dashboard preview.
Vulnerability Details
Published Date
Last Modified
CWE ID
CWE-79
Source
NVD
External References
- https://plugins.trac.wordpress.org/browser/mailerpress/tags/2.0.3/src/Actions/Shortcodes/CampaignEmail.php#L161
- https://plugins.trac.wordpress.org/browser/mailerpress/tags/2.0.3/src/Api/Campaigns.php#L2100
- https://plugins.trac.wordpress.org/browser/mailerpress/tags/2.0.3/src/Api/Campaigns.php#L2128
- https://plugins.trac.wordpress.org/browser/mailerpress/tags/2.0.3/src/Api/Campaigns.php#L2137
- https://plugins.trac.wordpress.org/browser/mailerpress/tags/2.0.5/src/Api/Campaigns.php#L2229
- https://plugins.trac.wordpress.org/browser/mailerpress/tags/2.0.5/src/Api/Campaigns.php#L4713
- https://plugins.trac.wordpress.org/browser/mailerpress/trunk/src/Actions/Shortcodes/CampaignEmail.php#L161
- https://plugins.trac.wordpress.org/browser/mailerpress/trunk/src/Api/Campaigns.php#L2100
- https://plugins.trac.wordpress.org/browser/mailerpress/trunk/src/Api/Campaigns.php#L2128
- https://plugins.trac.wordpress.org/browser/mailerpress/trunk/src/Api/Campaigns.php#L2137
- https://www.wordfence.com/threat-intel/vulnerabilities/id/c52cadb2-703f-4aad-85f2-aec1dd4befdc?source=cve
Discussion (0)
Add Comment
No comments yet. Be the first!